Hot Investor Mandate: Europe-Based VC Invests Up to €12M in Therapeutics Companies, Also Working as a Company Builder in Promising Early-Stage Project

3 Mar

A firm with offices in Europe currently manages a fund that focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2.  (i.e Series A and Series B)

Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: